The Drug-Induced Respiratory Disease Website
(Fr: fibrose pulmonaire). The background incidence of idiopathic pulmonary fibrosis (IPF) has to be taken into account for causality assessment. Imaging at PMID 23672718. The diagnosis of interstitial pulmonary fibrosis�is raised in the presence of linear pulmonary opacities and architectural distortion on imaging incl. HRCT, restrictive lung dysfunction, low KCO, and hypoxemia obviating the need for a lung biopsy. Presentation can be chronic, subacute or rapidly progressive. Generally, the condition develops insidiously with dyspnea and bibasilar or diffuse reticular or streaky opacities. Honeycombing can develop with time in longterm survivors. DI-fibrosis may follow a classic episode of chemotherapy- or amiodarone-induced pulmonary toxicity. Separation of DI-fibrosis from idiopathic or CTD (viz. RA or scleroderma)-related fibrosis can be arduous (PMID 23791462).�Patients may exacerbate and progress to ARDS. DI-fibrosis may develop late after completion of therapy with chemo agents, irradiation or amiodarone with no evidence of toxicity during treatment or in the meantime. DI-fibrosis rarely occurs as a complication of patterns Ia, b or c. Oxygen and irradiation can trigger the onset of or exacerbate DI-fibrosis. When DI-fibrosis develops during treatment with the offending agent, drug withdrawal may translate into some improvement. Costicosteroid therapy is indicated, but the results are unpredictable
Publications
Long term nitrofurantoin induced interstitial lung disease: a case series and literature review.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2023 Dec 20;40;e2023050 — 2023 Dec 20 — e2023050
Nitrofurantoin-induced pulmonary fibrosis.
Australian journal of general practice 2022 Mar;51;149-151 — 2022 Mar — 149-151
Speirs TP, Tuffin N, Mundy-Baird F, Sakota H, Mulholland S, Westlake M, Lyon M, Medford AR, Sharp C, Darby M, Albur M, Keeley F, Burden H, Kenward C, Jonas E, Barratt S, Adamali HI
Long-term nitrofurantoin: analysis of complication awareness, monitoring and pulmonary injury cases.
BJGP open 2021 Aug 18;; — 2021 Aug 18
Unrecognized Interstitial Lung Disease as a Result of Chronic Nitrofurantoin Use.
Drug safety - case reports 2016 Dec;3;13 — 2016 Dec — 13
Chronic nitrofurantoin-induced lung disease.
Mayo Clinic proceedings 2005 Oct;80;1298-302 — 2005 Oct — 1298-302
PLEUROPULMONARY REACTION TO NITROFURANTOIN.
JAMA 1964 Jul 20;189;239-40 — 1964 Jul 20 — 239-40
Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.
Journal of computer assisted tomography 2000 Mar-Apr;24;259-61 — 2000 Mar-Apr — 259-61
[Adverse effects of nitrofurantoin--cases reported to the Adverse Drug Reaction Committee during the period 1968-1992].
Ugeskrift for laeger 1995 Feb 06;157;761-3 — 1995 Feb 06 — 761-3
Adverse reactions to nitrofurantoin. Analysis of 921 reports.
The American journal of medicine 1980 Nov;69;733-8 — 1980 Nov — 733-8
Pulmonary fibrosis following long-term nitrofurantoin therapy.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1982 May 08;61;714-7 — 1982 May 08 — 714-7
[Chronic interstitial pneumonia with pulmonary fibrosis following long-term nitrofurantoin therapy].
Medizinische Klinik 1971 May;66;818-22 — 1971 May — 818-22
Pulmonary fibrosis and nitrofurantoin.
The American review of respiratory disease 1973 Aug;108;353-6 — 1973 Aug — 353-6
Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.
Scandinavian journal of respiratory diseases 1977;58;41-50 — 1977 — 41-50
Winterbauer RH, Hammar SP, Hallman KO, Hays JE, Pardee NE, Morgan EH, Allen JD, Moores KD, Bush W, Walker JH
Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine.
The American journal of medicine 1978 Oct;65;661-72 — 1978 Oct — 661-72